Perspective Therapeutics (CATX) Competitors $3.90 -0.10 (-2.50%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$3.87 -0.03 (-0.79%) As of 07/15/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CATX vs. FNA, PLSE, BLFS, TNDM, MDXG, INMD, SSII, KMTS, IRMD, and SIBNShould you be buying Perspective Therapeutics stock or one of its competitors? The main competitors of Perspective Therapeutics include Paragon 28 (FNA), Pulse Biosciences (PLSE), BioLife Solutions (BLFS), Tandem Diabetes Care (TNDM), MiMedx Group (MDXG), InMode (INMD), SS Innovations International (SSII), Kestra Medical Technologies (KMTS), iRadimed (IRMD), and SiBone (SIBN). These companies are all part of the "medical equipment" industry. Perspective Therapeutics vs. Its Competitors Paragon 28 Pulse Biosciences BioLife Solutions Tandem Diabetes Care MiMedx Group InMode SS Innovations International Kestra Medical Technologies iRadimed SiBone Perspective Therapeutics (NYSE:CATX) and Paragon 28 (NYSE:FNA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership. Is CATX or FNA more profitable? Paragon 28 has a net margin of -25.31% compared to Perspective Therapeutics' net margin of -4,096.66%. Perspective Therapeutics' return on equity of -27.40% beat Paragon 28's return on equity.Company Net Margins Return on Equity Return on Assets Perspective Therapeutics-4,096.66% -27.40% -23.16% Paragon 28 -25.31%-37.90%-18.22% Do institutionals and insiders hold more shares of CATX or FNA? 54.7% of Perspective Therapeutics shares are held by institutional investors. Comparatively, 63.6% of Paragon 28 shares are held by institutional investors. 3.5% of Perspective Therapeutics shares are held by insiders. Comparatively, 15.3% of Paragon 28 shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more volatility & risk, CATX or FNA? Perspective Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Comparatively, Paragon 28 has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Do analysts recommend CATX or FNA? Perspective Therapeutics currently has a consensus target price of $12.56, suggesting a potential upside of 221.94%. Paragon 28 has a consensus target price of $12.75, suggesting a potential downside of 2.71%. Given Perspective Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Perspective Therapeutics is more favorable than Paragon 28.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Perspective Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.18Paragon 28 0 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.20 Which has preferable valuation and earnings, CATX or FNA? Perspective Therapeutics has higher earnings, but lower revenue than Paragon 28. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPerspective TherapeuticsN/AN/A-$46.51MN/AN/AParagon 28$256.18M4.29-$57.53M-$0.63-20.80 Does the media refer more to CATX or FNA? In the previous week, Perspective Therapeutics had 4 more articles in the media than Paragon 28. MarketBeat recorded 4 mentions for Perspective Therapeutics and 0 mentions for Paragon 28. Perspective Therapeutics' average media sentiment score of 0.88 beat Paragon 28's score of 0.00 indicating that Perspective Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Perspective Therapeutics Positive Paragon 28 Neutral SummaryPerspective Therapeutics beats Paragon 28 on 8 of the 14 factors compared between the two stocks. Get Perspective Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CATX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CATX vs. The Competition Export to ExcelMetricPerspective TherapeuticsSurgical & medical instruments IndustryMedical SectorNYSE ExchangeMarket Cap$296.91M$64.37M$5.62B$20.84BDividend YieldN/AN/A4.25%3.65%P/E RatioN/A5.0228.5727.17Price / SalesN/A86.98423.3048.23Price / CashN/A18.4136.0222.28Price / Book1.466.718.134.56Net Income-$46.51M-$24.59M$3.24B$995.22M7 Day Performance3.17%-1.28%0.16%-1.16%1 Month Performance8.03%-7.35%5.95%3.18%1 Year Performance-69.05%20.61%26.09%6.83% Perspective Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CATXPerspective Therapeutics2.3555 of 5 stars$3.90-2.5%$12.56+221.9%-68.4%$296.91MN/A0.0070News CoverageGap UpFNAParagon 28N/A$13.11+0.1%$12.75-2.7%+70.9%$1.10B$256.18M-17.71343,000High Trading VolumePLSEPulse Biosciences3.802 of 5 stars$16.07+0.2%$22.00+36.9%-22.0%$1.08B$700K0.00140BLFSBioLife Solutions2.164 of 5 stars$22.02+0.3%$31.17+41.5%-0.1%$1.05B$87.76M-75.93440Positive NewsTNDMTandem Diabetes Care4.153 of 5 stars$15.75+1.0%$32.71+107.7%-67.9%$1.05B$982.95M-5.672,650MDXGMiMedx Group3.6569 of 5 stars$6.80+2.1%$12.50+83.8%-11.2%$1.00B$348.88M25.19870News CoverageAnalyst ForecastGap DownINMDInMode4.0548 of 5 stars$14.74+0.2%$18.54+25.8%-20.1%$931.70M$392.41M6.33480Positive NewsSSIISS Innovations InternationalN/A$4.75-4.8%N/AN/A$919.60M$20.65M0.004Gap UpKMTSKestra Medical TechnologiesN/A$15.43+3.5%$27.50+78.2%N/A$792.32M$52.64M0.00300News CoverageIRMDiRadimed4.6989 of 5 stars$58.07+0.9%$72.00+24.0%+25.8%$738.65M$73.24M37.46110SIBNSiBone4.0758 of 5 stars$17.32+0.7%$22.50+29.9%+8.6%$738.18M$167.18M-27.06350Positive News Related Companies and Tools Related Companies FNA Alternatives PLSE Alternatives BLFS Alternatives TNDM Alternatives MDXG Alternatives INMD Alternatives SSII Alternatives KMTS Alternatives IRMD Alternatives SIBN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CATX) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Perspective Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Perspective Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CATX Stock Alerts